Medtronic Raises Fiscal 2027 Outlook Amid Heart Device Demand

Medtronic has revised its fiscal 2027 financial forecasts upwards, citing robust demand for its heart devices used in complex cardiovascular procedures. The medical technology giant now anticipates an annual organic revenue growth between 7.25% and 7.75%, an increase from its previous estimate of 6.75% to 7.25%.

Strategic Investments and Market Growth

In a strategic move, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, the company has invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device outside the US. Medtronic CEO Geoff Martha highlighted the potential of robotic surgery in emerging markets, where penetration remains below 1%.

Financial Performance and Outlook

Medtronic's financial performance has been bolstered by its cardiovascular segment, which saw a 19.5% increase in quarterly sales, reaching $3.93 billion. The growth was largely driven by an 88% increase in its pulsed field ablation portfolio, used to treat irregular heart rhythms. The company reported an adjusted quarterly per-share profit of $1.45 on revenues of $9.76 billion, surpassing analyst expectations of $1.39 per share on $9.55 billion in revenue, according to LSEG data.

Impact of Tariff Refunds

Thierry Pieton, Medtronic's finance chief, noted that the company received tariff refunds that nearly covered the duties incurred during the quarter. However, these refunds have not been factored into future financial projections.

Medtronic's strategy involves prioritizing high-growth segments within the medical technology field, focusing on large patient populations. CEO Geoff Martha emphasized the company's steady approach to mergers and acquisitions, targeting substantial market segments with significant growth potential.